Study of a 4-Week Lead-In With Nitazoxanide Followed By 36 Weeks of Nitazoxanide Plus Peginterferon Alfa-2a in the Treatment of Chronic Hepatitis C.

Trial Profile

Study of a 4-Week Lead-In With Nitazoxanide Followed By 36 Weeks of Nitazoxanide Plus Peginterferon Alfa-2a in the Treatment of Chronic Hepatitis C.

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Nov 2008

At a glance

  • Drugs Nitazoxanide; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Romark Laboratories
  • Most Recent Events

    • 03 Nov 2008 Results were presented at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) and the 50th Anniversary Meeting of the International Association for the Study of the Liver (IASL).
    • 17 Oct 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top